Credit: Original article published here.The Oncology Brothers are joined by Dr. Margaret Gatti-Mays, of the Ohio State Comprehensive Cancer Center, to cover the current standard of treatment care in hormone receptor positive breast cancer. In this episode, Dr. Gatti-Mays walks through approach for treating women with this type of cancer using a treatment algorithm based on both disease stage (early stage, locally advanced, advanced/metastatic), and patient age (premenopausal vs. postmenopausal). Dr. Gatti-Mays expressed her excitement for being a breast oncologist based on “the amazing advancements that have occurred within the last couple of years.”
Credit: Original article published here.In this engaging episode, The Oncology Brothers welcome Dr. Jason Mouabbi, a breast medical oncologist from the MD Anderson Cancer Center, to better understand different histologies in hormone receptor-positive breast cancers, with a specific focus on invasive lobular carcinoma. This subtype of breast cancer, which is very different from the more common ductal carcinoma, as stated by Dr. Mouabbi, “is a very important [breast cancer subtype], that is largely misunderstood and understudied.”
Credit: Original article published here.The Oncology Brothers are joined by Dr. Paolo Tarantino, European Institute of Oncology, Clinical Research Fellow at Dana-Farber Cancer Institute, to walk through his approach for treating HER 2 Neu positive breast cancer with an algorithm. After analyzing the algorithm, which is broken down by disease stage (early stage, locally advanced, and advanced disease) the group reviewed a relevant case from the community setting.
Credit: Original article published here.In this episode, the Oncology Brothers spoke with world-renowned thoracic oncologist Dr. Jarushka Naidoo of Ireland to learn about her approach for treating me metastatic non-small cell lung cancer (NSCLC) with actionable mutations in the first-line setting. This algorithm is important in the space of thoracic oncology, because as stated by Dr. Naidoo, NSCLC is “the poster child for precision medicine.”
Credit: Original article published here.In this insightful episode, The Oncology Brothers are joined by Dr. Eric Singhi, Assistant Professor – University of Texas, MD Anderson Cancer Center, to discuss a treatment algorithm for metastatic non-small cell lung cancer without targetable mutations in the first-line setting.
Credit: Original article published here.In this podcast episode, The Oncology Brothers are joined by Dr. Estelamari Rodriguez, University of Miami Health System, to discuss her approach for treating small cell lung cancer (SCLC). Dr. Rodriguez, who serves as the Associate Director of Community Outreach – Thoracic Oncology at Sylvester Comprehensive Cancer Center, is a patient advocacy award-winning thoracic oncologist. She explains how she treats patients based on disease stage (Limited Stage vs. Extensive Stage), and the group discusses common scenarios from the community setting and how available treatment options can benefit the SCLC patient population.
Credit: Original article published here.The Oncology Brothers are joined by nationally-renowned researcher and thoracic oncologist Charu Aggarwal, MD, MPH, of Penn Center for Precision Medicine, to discuss a treatment algorithm for localized non-small cell lung cancer (NSCLC). The trio detail the best treatment approaches for stage I-III NSCLC – stages where therapy is administered with curative intent.
